Icu Medical Stock Price, News & Analysis

ICU Medical, Inc. (Nasdaq:ICUI) reported significant financial results for Q4 2022, with revenues reaching $578 million, up from $340.5 million year-over-year. Despite this strong revenue growth, the company experienced a GAAP net loss of $(15.5 million) or $(0.65 per diluted share), contrasting with a net income of $19.9 million or $0.91 per diluted share in Q4 2021. The GAAP gross margin declined to 30% from 37% a year prior. Adjusted diluted EPS was $1.60, down from $1.82. The company expects a net loss between $(73) million and $(37) million for FY 2023, with adjusted EBITDA forecasted between $375 million and $425 million.

ICU Medical, a leader in medical products, will present at the Raymond James 44^th Annual Institutional Investors Conference in Orlando, Florida, from March 5-8, 2023. The presentation is scheduled for March 6, 2023, at 8:00 a.m. PT (11:00 a.m. ET). Management will also engage in one-on-one meetings on the same day. The presentation will be available via a live webcast on the company's website, allowing for future replays. ICU Medical specializes in infusion systems and critical care products, catering to diverse healthcare environments.

ICU Medical, Inc. (Nasdaq:ICUI) has announced the timing of its fourth quarter 2022 earnings release and conference call. The results will be disclosed on February 27, 2023, at around 4:00 p.m. ET, followed by a conference call at 4:30 p.m. ET. Investors can join the call by phone at (877) 300-8521 with conference ID 10174731 or via webcast on the company's website. ICU Medical is recognized for its innovative medical products, particularly in infusion systems and critical care products. This earnings announcement is crucial for stakeholders looking to gauge the company's performance and future outlook.

ICU Medical (Nasdaq: ICUI), a leader in medical product development, has announced its participation in the J.P. Morgan 41^st Annual Healthcare Conference in San Francisco from January 9-12, 2023. The company's presentation is scheduled for January 11, 2023, at 1:30 p.m. PST (4:30 p.m. EST) and will be available via a live webcast on its website. ICU Medical specializes in infusion systems and critical care products, aiming to deliver quality and innovation to clinical customers globally. More information can be found on their website.

ICU Medical reported third quarter 2022 revenue of $597.9 million, significantly up from $336.1 million year-over-year. GAAP gross profit rose to $186.4 million but gross margin decreased to 31% from 38%. The firm posted a GAAP net loss of $(13.2) million or $(0.55) per share, compared to a net income of $31.1 million a year earlier. Adjusted diluted EPS was $1.75, down from $2.07. The company reaffirmed its 2022 guidance, estimating a net loss between $(95) million and $(81) million.

ICU Medical (Nasdaq: ICUI) announced its third quarter 2022 earnings release will occur on November 7, 2022, at 4:00 p.m. ET. The conference call is set for 4:30 p.m. ET on the same day. Investors can join the call by dialing (877) 300-8521 and entering conference ID 10171949. A webcast of the call will also be available on the company's website, with a replay option to follow. ICU Medical is renowned for its infusion systems and critical care products used globally in healthcare settings.

ICU Medical, Inc. (Nasdaq:ICUI) has announced that its management will participate in a fireside chat at the Morgan Stanley Annual Global Healthcare Conference on September 12, 2022, at 11:15 a.m. PT (2:15 p.m. ET). The event will be accessible via a live webcast on the company's website, with a replay available afterward. Additionally, one-on-one meetings will also be held on the same day. ICU Medical specializes in infusion systems and critical care products, serving various healthcare settings.

ICU Medical reported strong second quarter results for 2022, with revenues of $561 million, up from $321.7 million year-over-year. GAAP gross profit increased to $167.6 million, but gross margin fell to 30% from 38%. The company incurred a net loss of $7.5 million compared to a profit of $28.4 million in Q2 2021. Adjusted EBITDA rose to $84.7 million, although adjusted earnings per share decreased from $1.88 to $1.37. The company updated its 2022 guidance, lowering adjusted EBITDA expectations to $350-$370 million and adjusted earnings per share to $6.20-$6.80.